CBAY Annual EBITDA
-$85.74 M
+$4.72 M+5.22%
31 December 2023
Summary:
As of January 21, 2025, CBAY annual earnings before interest, taxes, depreciation & amortization is -$85.74 million, with the most recent change of +$4.72 million (+5.22%) on December 31, 2023. During the last 3 years, it has fallen by -$35.39 million (-70.28%).CBAY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY Quarterly EBITDA
-$36.77 M
-$7.94 M-27.55%
31 December 2023
Summary:
As of January 21, 2025, CBAY quarterly earnings before interest, taxes, depreciation & amortization is -$36.77 million, with the most recent change of -$7.94 million (-27.55%) on December 31, 2023. Over the past year, it has dropped by -$7.94 million (-27.55%).CBAY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY TTM EBITDA
-$85.74 M
-$14.31 M-20.03%
31 December 2023
Summary:
As of January 21, 2025, CBAY TTM earnings before interest, taxes, depreciation & amortization is -$85.74 million, with the most recent change of -$14.31 million (-20.03%) on December 31, 2023. Over the past year, it has dropped by -$14.31 million (-20.03%).CBAY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.2% | -27.6% | -20.0% |
| 3 y3 years | -70.3% | -135.9% | -66.1% |
| 5 y5 years | -18.9% | -89.7% | +16.4% |
CBAY EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +832.4% | -1014.3% | +3487.6% |
CymaBay Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$85.74 M(-5.2%) | -$36.77 M(+27.5%) | -$85.74 M(+20.0%) |
| Sept 2023 | - | -$28.82 M(-816.8%) | -$71.44 M(+13.2%) |
| June 2023 | - | $4.02 M(-116.6%) | -$63.12 M(-30.2%) |
| Mar 2023 | - | -$24.18 M(+7.6%) | -$90.41 M(-0.1%) |
| Dec 2022 | -$90.47 M(+4.3%) | -$22.46 M(+9.5%) | -$90.47 M(-2.0%) |
| Sept 2022 | - | -$20.50 M(-11.9%) | -$92.34 M(-1.6%) |
| June 2022 | - | -$23.27 M(-4.0%) | -$93.82 M(+0.2%) |
| Mar 2022 | - | -$24.23 M(-0.4%) | -$93.59 M(+7.9%) |
| Dec 2021 | -$86.75 M(+72.3%) | -$24.33 M(+10.7%) | -$86.75 M(+11.2%) |
| Sept 2021 | - | -$21.98 M(-4.6%) | -$78.00 M(+15.9%) |
| June 2021 | - | -$23.05 M(+32.6%) | -$67.28 M(+21.8%) |
| Mar 2021 | - | -$17.39 M(+11.5%) | -$55.23 M(+7.0%) |
| Dec 2020 | -$50.35 M(-50.9%) | -$15.59 M(+38.4%) | -$51.62 M(-15.9%) |
| Sept 2020 | - | -$11.26 M(+2.4%) | -$61.35 M(-21.0%) |
| June 2020 | - | -$11.00 M(-20.2%) | -$77.65 M(-15.7%) |
| Mar 2020 | - | -$13.77 M(-45.6%) | -$92.16 M(-10.1%) |
| Dec 2019 | -$102.50 M(+42.2%) | -$25.32 M(-8.1%) | -$102.50 M(+6.1%) |
| Sept 2019 | - | -$27.56 M(+8.1%) | -$96.57 M(+10.3%) |
| June 2019 | - | -$25.51 M(+5.8%) | -$87.55 M(+10.2%) |
| Mar 2019 | - | -$24.11 M(+24.4%) | -$79.44 M(+10.2%) |
| Dec 2018 | -$72.11 M | -$19.38 M(+4.5%) | -$72.11 M(+25.4%) |
| Sept 2018 | - | -$18.55 M(+6.7%) | -$57.52 M(+22.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$17.39 M(+3.6%) | -$46.94 M(+22.9%) |
| Mar 2018 | - | -$16.79 M(+249.7%) | -$38.19 M(+44.4%) |
| Dec 2017 | -$26.44 M(+4.5%) | -$4.80 M(-39.8%) | -$26.44 M(-6.4%) |
| Sept 2017 | - | -$7.97 M(-7.7%) | -$28.26 M(+9.5%) |
| June 2017 | - | -$8.64 M(+71.5%) | -$25.82 M(+8.3%) |
| Mar 2017 | - | -$5.04 M(-23.9%) | -$23.83 M(-5.8%) |
| Dec 2016 | -$25.30 M(+73.4%) | -$6.62 M(+19.7%) | -$25.30 M(+4.0%) |
| Sept 2016 | - | -$5.53 M(-16.9%) | -$24.33 M(-0.3%) |
| June 2016 | - | -$6.65 M(+2.1%) | -$24.40 M(+28.8%) |
| Mar 2016 | - | -$6.51 M(+15.3%) | -$18.94 M(+29.8%) |
| Dec 2015 | -$14.59 M(-53.1%) | -$5.64 M(+0.9%) | -$14.59 M(-32.0%) |
| Sept 2015 | - | -$5.59 M(+371.3%) | -$21.48 M(-0.8%) |
| June 2015 | - | -$1.19 M(-45.2%) | -$21.65 M(-7.6%) |
| Mar 2015 | - | -$2.17 M(-82.7%) | -$23.44 M(-24.7%) |
| Dec 2014 | -$31.14 M(+238.7%) | -$12.53 M(+117.3%) | -$31.14 M(+39.4%) |
| Sept 2014 | - | -$5.76 M(+93.6%) | -$22.34 M(+26.5%) |
| June 2014 | - | -$2.98 M(-69.8%) | -$17.66 M(+5.9%) |
| Mar 2014 | - | -$9.88 M(+165.0%) | -$16.68 M(+81.4%) |
| Dec 2013 | -$9.20 M(-10.7%) | -$3.73 M(+245.4%) | -$9.20 M(+68.2%) |
| Sept 2013 | - | -$1.08 M(-46.0%) | -$5.47 M(+24.6%) |
| June 2013 | - | -$2.00 M(-16.4%) | -$4.39 M(+83.6%) |
| Mar 2013 | - | -$2.39 M | -$2.39 M |
| Dec 2012 | -$10.29 M | - | - |
FAQ
- What is CymaBay Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for CymaBay Therapeutics?
- What is CymaBay Therapeutics annual EBITDA year-on-year change?
- What is CymaBay Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for CymaBay Therapeutics?
- What is CymaBay Therapeutics quarterly EBITDA year-on-year change?
- What is CymaBay Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for CymaBay Therapeutics?
- What is CymaBay Therapeutics TTM EBITDA year-on-year change?
What is CymaBay Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CBAY is -$85.74 M
What is the all time high annual EBITDA for CymaBay Therapeutics?
CymaBay Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$9.20 M
What is CymaBay Therapeutics annual EBITDA year-on-year change?
Over the past year, CBAY annual earnings before interest, taxes, depreciation & amortization has changed by +$4.72 M (+5.22%)
What is CymaBay Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CBAY is -$36.77 M
What is the all time high quarterly EBITDA for CymaBay Therapeutics?
CymaBay Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $4.02 M
What is CymaBay Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CBAY quarterly earnings before interest, taxes, depreciation & amortization has changed by -$7.94 M (-27.55%)
What is CymaBay Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CBAY is -$85.74 M
What is the all time high TTM EBITDA for CymaBay Therapeutics?
CymaBay Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.39 M
What is CymaBay Therapeutics TTM EBITDA year-on-year change?
Over the past year, CBAY TTM earnings before interest, taxes, depreciation & amortization has changed by -$14.31 M (-20.03%)